ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company focuses on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors and chemo-attractant receptors. The Company has five drug candidates in clinical development, which include CCX168, CCX140, CCX872, Traficet-EN and CCX507. CCX168 targets the chemo-attractant C5a receptor, which binds to a fragment of the complement protein known as C5. CCX140 targets the chemokine receptor known as CCR2. CCX872 is the Company�s second generation CCR2 inhibitor for the treatment of metabolic diseases, such as atherosclerosis and cardiovascular disease. Traficet-EN is intended to control the inflammatory response by targeting the chemokine receptor known as CCR9. CCX507 works in the area of CCR9 inhibitors.